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Abstract 
Hidradenitis suppurativa (HS) is a chronic and recurrent inflammatory disease of the skin 
containing apocrine glands.  It presents with nodules, painful abscesses, sometimes with 
purulent discharge, scar formation and fibrosis depending of the severity and stage. The 
most common sites affected are the apocrine-bearing areas such as the axillae and groin. 
Little is known about the pathogenesis of HS and the exact cause is widely debated. 
Follicular hyperkeratosis giving rise to follicular occlusion has been speculated to be the 
initial event. There is need for a wider array of treatment options since the condition is 
chronic and hard-to-treat in its nature. In this retrospective study we examined whether 
Intense pulsed light, IPL is an effective adjunctive treatment.   
 
47 patients from the years of 2001-2012 that have been treated with IPL or CO2 were finally 
included in the study. The Sartorius score was measured at baseline, 24.7. After a mean of 
3.53 treatments (median = 3) the Sartorius score was 5.64 points lower (CI 95%: -7.27;-4.00) 
Unfortunately, no significant lowering of the score was seen per treatment session and 
therefore it is impossible to draw any certain conclusions that the IPL or CO2-treatments 
caused the improvement.  
 
One cannot draw any certain conclusion from this study, a larger study population or a 
different study design is needed. The need for future research regarding the efficacy of IPL is 
still huge given the fact that only one study in the subject has been published so far. It 
should desirable to offer the patients suffering from the disease a wider array of noninvasive 
treatment options and decreasing the use of antibiotics. 
  
Populärvetenskaplig sammanfattning 
Hidradenitis suppurativa (HS) är en kronisk och återkommande hudsjukdom som påverkar 
hudytor där apokrina körtlar återfinns. Den presenterar sig med alltifrån rodnad, bölder med 
varierande storlek, illaluktande varbildning till kraftig ärrbildning. De vanligaste 
lokalisationerna är armhålor, under brösten, ljumskar och kring genitalia.  
 
Sjukdomen drabbar både män och kvinnor, där risken är tre gånger större att drabbas som 
kvinna, vanligtvis i åldern 15-45 år. Orsaken till sjukdomen är i stora drag fortfarande 
omdebatterad och okänd, men idag tror man att en tilltäppning av hårfollikeln som en följd 
av hyperkeratos är det första steget i sjukdomsutvecklingen. Man har även identifierat vissa 
riskfaktorer som både korrelerar med risken för insjuknande och svårighetsgrad. Dessa är 
exempelvis rökning, kvinnligt kön och övervikt.  
 
Idag finns det en bred behandlingsarsenal mot HS såsom kirurgi, antibiotika, steroider och 
tömning av bölderna. Trots detta är sjukdomen fortfarande svårbehandlad och den orsakar 
patienterna ett stort lidande, både fysiskt och psykiskt. Nya behandlingsmetoder är önskvärt 
främst ur två aspekter. Dels för att eventuellt förbättra situationen för patienterna, men det 
är även önskvärt att kunna minska antibiotikaanvändningen och kirurgiska ingrepp hos 
dessa. 
 
I denna studien undersöktes det om Intense Pulse light (IPL) är en effektiv tilläggsbehandling 
vid HS. IPL är en ljuskälla som strålas mot huden och kan, beroende på inställning, orsaka 
olika fysiologiska mekanismer. I den här studien användes IPL för hårborttagning, 
ärrförbättring och för att behandla aktiva bölder. 
 
Studien var retrospektiv i sitt slag och totalt 47 patienter inkluderades. Dessa hade alla 
besökt Hudkliniken på SUS Malmö under åren 2002-2010 och blivit behandlade med IPL mot 
sin HS. Sjukdomens svårighetsgrad mättes med hjälp av Sartoriussystemet. Innan start av 
IPL-behandling låg den genomsnittliga poängen på 24.7, efter i genomsnitt 3.53 (median = 3) 
behandlingar hade patienternas poäng sjunkit med 5.64 poäng till 19.06. Denna minskning 
var statistiskt signifikant. 
 
Däremot för att avgöra om minskningen berodde på ljusbehandlingen, och inte på andra 
faktorer så undersöktes det vidare hur förändringen i poäng/svårighetsgrad var per 
behandlingstillfälle. Här kunde man inte påvisa någon signifikant minskning från tillfälle till 
tillfälle. 
 
Alltså kan man inte dra några säkra slutsatser från den här studien. Det är möjligt att IPL 
hjälper men vi fick det inte bekräftat. Fler studier med mer avancerad studiedesign och mer 
information från patientjournalerna behövs för att kunna få den styrka i undersökningen 
som önskas.  
Introduction 
Hidradenitis suppurativa (HS) is a chronic and recurrent inflammatory disease of the skin 
containing apocrine glands.  It presents with nodules, painful abscesses, sometimes with 
purulent discharge, scar formation and fibrosis depending of the severity and stage. The 
most common sites affected are the apocrine-bearing areas such as the axillae and groin. 
Other common sites affected are the sub-mammary and infra-mammary folds, buttocks, and 
perianal and perineal areas. The inguino-femoral site is the most common area involved 
both among men and women. The buttocks and perianal area are more common sites 
among men compared with women, while patients with mammary involvement are more 
likely among women. However, the patients can have multiple lesions at multiple sites 
varying over time.1  
 
Classification and pathogenesis 
Little is known about the pathogenesis of HS and the exact cause is widely debated. 
Follicular hyperkeratosis giving rise to follicular occlusion has been speculated to be the 
initial event. This can lead to secondary apocrine stasis and follicular rupturing leading to 
inflammation and subsequent infection.2 The events leading to the characteristic scaring 
formation is speculated to be exacerbated by the sinus tracts formed during the course of 
disease.3 The fact that the lesions often are symmetrical distributed supports the idea that it 
is a systemic disease rather than local. 1 
The disease can clinically be 
characterized into three 
stages depending on the 
severity, also called Hurley 
stages (I-III).  See table 1. At 
Hurley stage I, there are 
acute primary lesions, 
often deep-seated nodules 
that can progress to 
abscesses. The primary 
nodules often resolve spontaneously with a mean duration of 7 days, while abscesses often 
Table 1. Description of the Hurley stages 
Hurley stages 
 
Stage Definition 
I Abscess formation without sinus tracts and 
cicatrization 
II Recurrent abscesses with tract formation and 
cicatrization. 
III Diffuse involvement or interconnected tracts and 
abscesses across the entire anatomical region. 
1 Anatomical region involved. 3 
points per region. 
2 Number of lesions.  Points per 
lesion. Fistulas 4 points. Nodules 2 
points. Scars and others 1 point. 
3 The longest distance between two 
lesions in each region. 0-5 cm, 2 
points. 5-10 cm, 4 points. > 10 cm, 8 
points. 
4 Are all lesions separated by 
normal skin? In each region, yes 0 
points/no 6 points.  
require surgical intervention. 4 In stage II, sinus tracts and fibrosis are ultimately formed in 
some patients. The underlying mechanisms are the chronicity and recurrence of the 
condition where nodules and abscesses are formed at the same sites multiple times. At this 
second stage, the affected skin is often colonized by gram-negative bacterias causing a foul 
odor and social stigmatizing. Finally, the third Hurley stage is described by the characteristics 
of stage I and II plus hypertrophic scar formation. These scar formations can both be very 
painful for the patient and obstruct movement, i.e. arm abduction in cases with severe 
axillary scar formation. According to an epidemiological study by Canoui-Poitrine et al, about 
two thirds of the patients are classified as Hurley stage I and 3.9 percent were in stage III. 1  
Another system for staging HS, called the Sartorius staging    Textbox 1. Sartorius score. 
system (see textbox 1), has been developed by Sartorius 
 and colleagues.5 This staging system is more 
sophisticated than Hurley’s and is therefore more suitable 
for clinical trials.  The points are accumulated to provide 
both a local and global score, where a higher score means 
more severe disease. Sartorius has been shown to have a 
low interobserver variability.6  
Epidemiology 
HS is a disease with a one-year prevalence of 1%, and it is 
  more common among women with a female-male ratio  
of 3.3:1. 1 The onset is typical insidious in the second or third decade of life, prepubertal 
onset is rare because of the fact that the apocrine glands normally aren’t active until 
puberty.7 Because of the appearance of the disease, it is often misdiagnosed and common 
differential diagnoses are carbuncles, common abscesses and cysts, such as epidermoid 
cysts.  
Risk factors and comorbidity 
Studies have shown a strong correlation between smoking, obesity, family history of HS and 
incidence of HS. There is also a correlation between a higher body mass index (BMI) and the 
severity of the disease. Furthermore, smoking patients experience a more severe course of 
the disease than non-smoking patients.8 The exact etiological mechanisms behind these 
findings remain unclear. Lately, recent studies has proposed an involvement of the tumour-
necrosis-factor α (TNF-α) and earlier investigations have reported associations with Crohn’s 
disease. This has led to the idea that HS is an immunological disorder to some extent.9 10 It is 
debated whether there are some hormonal influences on the pathogenesis. There is a 
female overrepresentation and an association with oral contraceptive use has been reported 
but studies have failed to show direct biological evidence for the hypothesis.11 12   
For the individuals suffering from HS, the condition has a considerable impact on the quality 
of life. A study of a Polish population from Matusiak et al. showed that HS had no effect at all 
on quality of life in only 1.9 percent of the patients with active HS, while 59.2 % of the study 
population expressed “very large” or “extremely large” effect on everyday life. At the same 
time, the disease caused absence from work among 58.1 % of the patients.13 Another study 
showed that HS has a larger impact on life than for example alopecia or moderate 
psoriasis.14 
Treatment 
The treatment of HS varies depending on stage and severity and there are no existing 
guidelines today and much of the chosen treatments are based on clinical experience.15 
Overall, treatment is usually not successful and has a high level of dissatisfaction. Among 
patients in the first Hurley stage, topical antibiotic has shown to be effective with the 
addition of oral antibiotic in more severe cases. Another choice of therapy that is widely 
used by dermatologists is the injection of glucocorticoids in nodules. Furthermore, anti-
androgens and isoretinoin are also often used as therapy, but isoretinoin has failed to show 
efficacy in studies.16 The idea that HS is partly or fully an immunological disorder has led to 
case reports and small population studies studying the effect of immunosuppressive agents 
such as interleukin-pathways-inhibitors with varying results.17 18  In more severe cases the 
condition often requires surgery, such as incision of abscesses, localized excision and 
sometimes even skin transplantation.  
Recently, the use of laser and radiation therapy has been adopted for treatment in HS even 
though the research still is limited. For example, Lapins et al showed that only 12% of the 
patients treated with carbon dioxide laser developed new lesions at the treated site with a 
mean follow-up 34.5 months.19 Highton et al suggests in a study with 18 participants that 
intensed pulsed light (IPL) might be effective against HS, showing significant improvement in 
the treated areas.20  Furthermore, a study from Strauss et al. showed no improvement in 
treating four patients with photodynamic therapy.21 
 
IPL-devices emit a polychromatic high-frequency pulsed light as opposite to laser devices 
that emits a monochromatic light. The wavelength, pulse duration and frequency can be 
determined which gives the opportunity to be very selective regarding thermal damage 
comparing to lasers. The conditions treated with IPL vary from hair removal, skin 
rejuvenation, vascular lesions, acne vulgaris, and pigmented lesions while it also shows anti-
bacterial effects.22  Our hypothesis is that depilation with IPL can be a relief for patients with 
HS because of the follicular and apocrine origin, together with the possible anti-bacterial 
effects. Based on all this, we aim to examine whether IPL is an effective adjunctive therapy 
for patients with HS and can reduce the use of surgery, antibiotic use, CO2-surgery and 
improve the quality of life in the patients.  
Material and methods 
IPL has been used as an adjunctive therapy in the treatment of HS at the Skåne University 
Hospital in Malmö, Sweden. In this retrospective study we investigated the medical records 
of all patients admitted to the Dermatology department with confirmed HS between the 
years 2001-2012, a total of 286 patients (226 females, 60 males). The diagnoses were 
confirmed by the treating physicians based on clinical presentation and recorded in the 
medical records. All participating patients gave their consent that their medical records 
could be used for research purposes in the future. The exclusion criteria were one, or no 
treatment with IPL or lack of photographs with decent quality in the medical records making 
it impossible to score the patient. A total of 47 patients were finally included in the study. 31 
of the patients were treated with IPL, 16 patients were treated with both IPL and CO2-laser. 
Scores were given according to the Sartorius staging system based on high resolution 
photographs, in some cases with the additional information given by the text records.  In 
cases were not all affected areas were treated with IPL, a local score for the regions treated 
were calculated. Reasons for not treating areas with IPL were for example; patients that 
didn’t shaved the affected regions or their desires not to be treated. Other variables such as 
smoking status, number of years with the condition, overweight, earlier local and system 
therapies used were also obtained from the records. 
Results 
 The mean age of the study population was 34.4 years (median 31.0 years) and the self-
proclaimed mean duration of the condition was 10.1 years.  All the characteristics are 
described in table 2. The most common sites affected were the axillae, affecting 62% of the 
patients, and the groins affecting 53 % of the patients. The frequency of HS in different 
localisations is shown in table 3. The energy used in the IPL treatments were 3.5-21.5 Joule 
with pulse duration of 2-55 milliseconds. 
 
  
The patients received 1-10 treatments, mean IPL-treatments = 3.04, mean CO2-treatments = 
0.49, median = 3 treatments. The mean Sartorius baseline score was 24.7. Using Wilcoxon’s 
Table 2. The characteristics of the study population (n = 47)  
                     Characteristics                                          Frequency              Percent 
Age (years)   
 -Mean 34.4  
-Median 31.0  
Gender (n)   
-Female  38 80.9 
-Male 9 19.1 
Years with the disease (mean) 10.1  
Overweight (n)   
 -Yes 20 42.6 
 -No 2 4.3 
 -N/A 25 53.1 
Smoking status (n)   
-Current or former smoker 13 27.6 
-Never 2 4.3 
-N/A 32 68.1 
Earlier local treatment (n)   
-Surgery 12 25.5 
-N/A 35 74.5 
Earlier systemic treatment (n)   
-Antibiotics 33 70.2 
-Roaccutan 2 4.3 
-N/A 12 25.5 
Table 3. The frequency of HS in different anatomical regions among the study population (n = 47) 
Anatomical region Frequency (%) 
Axillae 29 (61.7) 
Groin 25 (53.2) 
Breasts 6 (12.8) 
Gluteal 2 (4.3) 
Abdominal 1 (2.1) 
Genitals 11 (23.4) 
signed rank test, the Sartorius score was 5.64 points lower after the treatments, (CI 95% -
7.27;-4.00). Furthermore, linear regression was used to estimate the change in Sartorius 
score per IPL-treatment and per CO2-treatment, one session of IPL changed the Sartorius 
score – 0.28 points (CI 95% -1.05;0.49) and one session of CO2 changed the Sartorius score – 
1.19 points (CI 95% -2.84-0.47). 
 
Discussion 
The patients had a lower Sartorius score after the course of treatment, but no significant 
effects of the single treatment occasions were seen among the patients, therefore it is 
impossible to conclude that the IPL or CO2-treatment caused the improvement seen in the 
patients. This does not mean that IPL or CO2 are useless against HS but one cannot draw any 
certain conclusions from this material.  One possible explanation is that the patients are 
more likely to be photographed after clear improvement of the condition or that the cyclical 
nature of the disease caused the differences in Sartorius score. This means that maybe the 
Sartorius score obtained are biased. Therefore, an analysis calculating the differences in the 
score per treatment were a much more reliable tool for investigating whether the 
improvement was caused by the IPL or CO2-treatments. Unfortunately, this numbers were 
not significant. Another aspect of this is that the documentation procedure of the records 
should be improved. This is especially of great importance when newer and non-evaluated 
treatments are used. 
 
The female-male-ratio among the original 286 patients was 3.77-to-1 which correlates well 
to earlier epidemiological studies. 1  There are some limitations to this study. Due to its 
retrospective nature, one cannot avoid a large number of patients falling off as a 
consequence of inadequate information in the records such as lack of detailed photographs 
and inadequate written information. Still, it is difficult to obtain a large study population 
prospectively when a rare disease is about to be investigated. The result of this is a less than 
desired study population. On other hand, the only published study so far that has 
investigated IPL as a treatment for HS only conducted 18 patients as compared with 47 in 
this study. ²: Unfortunately, another consequence of running retrospective studies based on 
medical records is the lack of information regarding different outcomes. The only possible 
outcome variable in these cases was the Sartorius score. One weakness is that the lack of 
sufficient number of photographs. A possible bias occurs when photographs are taken 
arbitrarily and when, during the course, different physicians choose to document the 
condition. It would have been desirable to test for other variables such as patient 
satisfactory, the amount of antibiotics used by the patients before and after and the need of 
future surgery for example. Nevertheless, the Sartorius score has shown to correlate well 
with disease burden such as pain intensity, numbers of days with pain and suppuration. 1 
Given the fact that there were a large number of patients that could not be scored according 
to the Sartorius score, this study design might have been too ambitious. If the Hurley stage 
classification were used instead, more patients would have been included and therefore the 
power of the study would have been increased.  
 
 It should be noted that all the patients included in this study received concomitant 
treatment during the course of the IPL treatments, mostly well-established regimes such as 
steroids (such as azelic acid cream), hydro peroxide cream and systemic antibiotics a few 
weeks after the CO2-treatment, therefore IPL was tested as an adjunctive therapy or as 
option to surgery. On the other hand, it should be mentioned that a very large amount of 
these patients have received these treatments before with little or no effect. Over the last 
years, most patients have not needed antibiotics after and in conjunction with CO2- and IPL-
treatments. Based on this, the results neither support our rejects our hypothesis that IPL is 
an effective adjunctive therapy for the patients. A larger study population or a different 
study design is required. Other variables that can possibly change the course of the disease 
are smoking and overweight. As mentioned before, these variables are associated with the 
severity of the disease and it is possible that weight reduction or smoking cessation in some 
patients has been left out in the records affecting the outcomes, even though most patients 
were recommended to lose weight and stop smoking, but very few succeeded or even tried 
to follow this recommendations.  
Why IPL? 
Compared to other treatment options, IPL offer a wide range of advantages. First of all, it is 
noninvasive and relatively safe for the patients with a low frequency of therapy sequelae 
and discomfort. Furthermore, the hair removal causes the patients to stop their shaving, 
which we know is not good for their HS. IPL also open up closed HS in the submamillary 
folds, an area that is hard-to-treat- with CO2-laser. The most common side effects are hypo- 
or hyperpigmentation, erythema, pain, blistering, atrophy and scarring. Of the 45 patients 
included in this study, none of them voluntarily discontinued IPL-treatment because of side 
effects. Depending on the indication and IPL settings, the rate of side effects and discomfort 
varies. A study by Moreno-Arias et al. investigated the incidence of side effects after 3-9 
treatments, comparable to our study, and found that erythema was only seen in 6.1% of the 
patients after 72 hours,  and only 2% experienced transient hyperpigmentation that lasted 
more than 16 weeks. In the same study, pain was described as mild among 87.8% of the 
patients.23 Furthermore, Troilius et al. presented an efficient method in a study of 10 
patients treated for hair removal with IPL with no discomfort or pain in none of the patients. 
This is the very same method that has widely been used among our study population.24 
Another positive aspect of IPL treatment is that it is easily manageable and patients can be 
treated by trained nurses, which is economically advantageous compared to surgery and 
CO2-laser. Some patients are keen to avoid surgery for different reasons. Depending on 
localization, surgical scars can cause great discomfort and surgery increases the risk of 
infection and recovery time needed. With the use of IPL, this is most often avoided. IPL also 
have the ability to soften the conglomerates of scarred tissue, reducing the pain and tension 
produced by these scars.  
 
The exact molecular mechanism behind the possible improvement seen in the patients 
remains unknown. Therefore, future biological studies investigating the exact mechanisms 
are required. However, earlier studies have shown that IPL used in skin rejuvenation, alters 
the gene expression in different genes responsible for the inflammatory response25. Most of 
the patients in this study received IPL treatment both with acne- and hair removal-settings. 
This means that there were subject to both hair removal and acne treatment. One possible 
mechanism is that the removal of the hair opens up the follicular occlusion, which is the first 
step of the disease, and aids draining thus preventing abscess formation. At the same time, 
the acne settings used facilitates the healing of already formed abscesses. Furthermore, one 
can speculate whether the hair itself acts as a foreign body, facilitating the inflammatory 
response.  
Future treatments 
Based on the possible molecular mechanism and etiology, several other treatment options 
that have been investigated recently is the used of immunosuppressive agents. The results 
so far are inconclusive. Gulliver et al. reported in a short report that the use of ustekinumab, 
an interleukin 12/23 pathway-inhibitor, is a potential therapeutic option in some patients.26 
Another case report by Sharon et al.  have shown promising results in a patient, with little or 
no respond to antibiotics, treated with infliximab, thus blocking TNF-a.27  
Conclusion 
HS is a hard-to-treat condition with several treatment options. Despite this, some patients 
fail to respond to the given therapy options. A wider array of potential options is therefore 
desirable. Our hope was to examine if IPL could be an effective adjunctive treatment that 
lowered the Sartorius score and disease burden. In other words, increasing the quality of 
life, decreasing the use of antibiotics and the need of traditional surgery such as excisions, 
incisions and skin transplantation. The argument for this is that the Sartorius score correlates 
well with the severity and need for these interventions. Unfortunately, no conclusions can 
be draw from this study. A longer and more detailed and structural follow-up procedure is 
required but it was practically difficult given the relatively small number of participants and 
limited follow-up time.  
  
Figures 
 
Figure 1. The appearance of HS in a 45-year old woman before and after three treatments with IPL. 
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